Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multi-Center, Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)

Trial Profile

A Phase 2, Multi-Center, Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Feb 2019

At a glance

  • Drugs Reldesemtiv (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Therapeutic Use
  • Acronyms FORTITUDE-ALS
  • Sponsors Cytokinetics
  • Most Recent Events

    • 10 Dec 2018 Analysis of the correlation between slow vital capacity (SVC) measured at home and in the clinic in this trial, published in a Cytokinetics media release.
    • 10 Dec 2018 According to a Cytokinetics media release, new data were presented at the 29th International Symposium on ALS/MND in Glasgow, Scotland, UK.
    • 27 Nov 2018 According to a Cytokinetics media release, Jeremy Shefner, M.D., Ph.D., Professor and Chair of Neurology at Barrow Neurological Institute, and Professor and Executive Chair of Neurology at University of Arizona is the lead Investigator of this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top